|Mandell, douglas, and bennett's principles and practice of infectious diseases: 2-volume set|
JE Bennett, R Dolin, MJ Blaser
Elsevier Health Sciences, 2014
|Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective|
Antimicrobial agents and chemotherapy 46 (2), 267-274, 2002
|Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis|
SH Gillespie, AM Crook, TD McHugh, CM Mendel, SK Meredith, ...
New England Journal of Medicine 371 (17), 1577-1587, 2014
|Routine use of microbial whole genome sequencing in diagnostic and public health microbiology|
CU Köser, MJ Ellington, EJP Cartwright, SH Gillespie, NM Brown, ...
PLoS pathogens 8 (8), e1002824, 2012
|Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial|
C Chintu, GJ Bhat, AS Walker, V Mulenga, F Sinyinza, K Lishimpi, ...
The Lancet 364 (9448), 1865-1871, 2004
|New world leishmaniasis|
R Lainson, JJ Shaw
Hodder Arnold ASM Press, 2005
|New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects|
AI Zumla, SH Gillespie, M Hoelscher, PPJ Philips, ST Cole, I Abubakar, ...
The Lancet infectious diseases 14 (4), 327-340, 2014
|Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis|
OJ Billington, TD McHugh, SH Gillespie
Antimicrobial agents and chemotherapy 43 (8), 1866-1869, 1999
|The bacteriology of pleural infection by genetic and standard methods and its mortality significance|
NA Maskell, S Batt, EL Hedley, CWH Davies, SH Gillespie, RJO Davies
American journal of respiratory and critical care medicine 174 (7), 817-823, 2006
|The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis|
RD Gosling, LO Uiso, NE Sam, E Bongard, EG Kanduma, M Nyindo, ...
American journal of respiratory and critical care medicine 168 (11), 1342-1345, 2003
|High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial|
MJ Boeree, N Heinrich, R Aarnoutse, AH Diacon, R Dawson, S Rehal, ...
The Lancet infectious diseases 17 (1), 39-49, 2017
|A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis|
MJ Boeree, AH Diacon, R Dawson, K Narunsky, J Du Bois, A Venter, ...
American journal of respiratory and critical care medicine 191 (9), 1058-1065, 2015
|Principles and practice of clinical parasitology|
SH Gillespie, RD Pearson
|Why do we use 600 mg of rifampicin in tuberculosis treatment?|
J Van Ingen, RE Aarnoutse, PR Donald, AH Diacon, R Dawson, ...
Clinical Infectious Diseases 52 (9), e194-e199, 2011
|Management of invasive pulmonary aspergillosis in hematology patients: a review of 87 consecutive cases at a single institution|
T Yeghen, CC Kibbler, HG Prentice, LA Berger, RK Wallesby, ...
Clinical infectious diseases 31 (4), 859-868, 2000
|Anti-tuberculosis medication and the liver: dangers and recommendations in management|
NP Thompson, ME Caplin, MI Hamilton, SH Gillespie, SW Clarke, ...
European Respiratory Journal 8 (8), 1384-1388, 1995
|Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study|
JM Bryant, SR Harris, J Parkhill, R Dawson, AH Diacon, P van Helden, ...
The Lancet Respiratory Medicine 1 (10), 786-792, 2013
|Principles and practice of clinical bacteriology|
S Gillespie, PM Hawkey
John Wiley & Sons, 2006
|Molecular epidemiology of tuberculosis in London 1995–7 showing low rate of active transmission|
H Maguire, JW Dale, TD McHugh, PD Butcher, SH Gillespie, A Costetsos, ...
Thorax 57 (7), 617-622, 2002
|Multivariate analysis of quality|
H Martens, M Martens